ProQR Therapeutics N.V. reported its financial and operating results for the year ended December 31, 2024, with total revenue reaching €19.5 million, a 196% increase from the full year 2023. The company recorded a net loss of €27.8 million, or €0.32 per diluted share, compared to a net loss of €27.7 million, or €0.35 per diluted share, in 2023.
Research and development costs for 2024 increased to €36.4 million from €25.1 million in 2023, reflecting increased investments in the Axiomer platform and advancing pipeline programs. General and administrative costs decreased to €13.7 million from €16.2 million in the prior year.
As of December 31, 2024, ProQR held €149.4 million in cash and cash equivalents, an increase from €118.9 million at the end of 2023. The company projects a financial runway into mid-2027 and anticipates up to four clinical trial data readouts in 2025 and 2026, including initial data for AX-0810 in Q4 2025, with the CTA for AX-0810 on track for Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.